CRISPR became big in 2025, bringing advances for serious Indian health risks, which will continue in the coming year ...

In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or LVEF - - On track to deliver ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCMFDA Approval Based on ...

Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel inhibitors of serum glucocorticoid inducible ...

With the UHN REB approval, issued through the Clinical Trials Ontario (CTO) Stream system, St. Michael’s Hospital in Toronto, Ontario will now proceed to complete operational approvals, training, and ...

Detailed price information for Cardiol Therapeutics (CRDL-Q) from The Globe and Mail including charting and trades.

WASHINGTON, Nov 22 (Reuters) - The United States is poised to launch a new phase of Venezuela-related operations in the coming days, four U.S. officials told Reuters, as the Trump administration ...

BLOOM (TAMPA) – When Charlie Curtis was just 15 years old, his life changed in an instant. While running a mandatory mile during his physical education class at Plant High School, the Tampa teen went ...

Experiments were performed using the following stable overexpression cell lines: 1) for hERG current experiments, human embryonic kidney 293 cells (HEK293) expressing the hERG1a subunit (provided by ...

Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis - The first (FENhance ...

Sheryl O’Loughlin of Santa Rosa remembers everything about that Friday night — the dinner, the wine, the company. It was late September and she and her husband, Patrick, were staying in their ...